Onchilles Pharma

We're unveiling at #AACR25 new preclinical data for the next-generation cytotoxic therapeutic, N17350, which leverages the #ELANE pathway and has the potential to selectively kill #cancer and stimulate the immune system. Onchilles plans to initiate a Phase 1 trial of N17350 this year to validate the ELANE pathway in humans. This trial will further explore the safety and efficacy of this innovative mechanism, representing a significant step toward realizing the potential of ELANE-based therapies. Read the release for more details: https://lnkd.in/gTZPiwFs #cancers #tumor #tumors #oncology #novelMoA #immunity #ELANEpathway #anticancer #clinicaltrials #skincancer #headandneckcancer #lungcancer #breastcancer #TNBC #ovarian

We’re excited to announce the appointment of Dr. Lev Becker as Chief Scientific Officer and Emily Roberts-Thomson as Senior Vice President of Development Operations! Dr. Becker, our scientific founder, will advance our innovative programs, including NEU-002 and N17350, as we prepare for clinical trials. Emily brings more than 23 years of expertise in clinical development, positioning us for success in a transformative year. Together, their leadership will help us harness the ELANE pathway to develop groundbreaking pan-cancer therapies with immune preservation. Read more about this pivotal moment: https://lnkd.in/gWNJu3Ki #Leadership #Biotech #Immunotherapy #CancerResearch #Immunotherapies #cancer #tumor #oncology #novelMOA #anticancer #adaptiveimmunity #ELANEpathway #ELANE

Today we announced new preclinical data presented at the ?????????????? ?????? ?????????????????????????? ???? ???????????? ???????? for the NEU-002 program – a systemically delivered, pan-cancer therapeutic targeting the #ELANE pathway, for potent and selective #cancer killing with the potential to treat a wide range of cancers. ?? Title: NEU-002 leverages a cancer-specific innate immune pathway to induce immunogenic cell death and stimulate anti-tumor immunity #?? Abstract #: 1297 ?? Date: Friday, November 8, 2024, 9:00 a.m. to 7:00 p.m. CST ?? Location: George R. Brown Convention Center in Houston Read the release and see the poster for more details: https://lnkd.in/dzFNwG7w #SITC24 #ELANEpathway #NextGeneration #CancerTherapy #CancerResearch #Immunotherapy #cancer #tumor #oncology #novelMOA #anticancer #systemicimmunity

Today we announced the presentation of new preclinical data at the ?????????????? ?????? ?????????????????????????? ???? ???????????? ???????? for the NEU-002 program, leveraging the ELANE pathway, a novel innate immune MOA for potent and selective cancer killing with the potential to treat a wide range of cancers. ?? Title: NEU-002 leverages a cancer-specific innate immune pathway to induce immunogenic cell death and stimulate anti-tumor immunity #?? Abstract #: 1297 ?? Date: Friday, November 8, 2024, 9:00 a.m. to 7:00 p.m. CST ?? Location: George R. Brown Convention Center in Houston Read the release for more details:? https://lnkd.in/gW_NbBnT #SITC24 #SITC2024 #Immunotherapy #CancerResearch #Immunotherapies #cancer #tumor #oncology #novelMOA #anticancer #adaptiveimmunity #ELANEpathway #ELANE

Our cofounder Lev Becker chatted with PharmaShots about the excitement around our #AACR24 data, the difference between N17350 and N17465, and details for our upcoming #clinicaltrial. Read the article here: https://lnkd.in/gwbWUTY4 #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

We presented today at the 20th BioPharma Drug Discovery Nexus Conference in #SanDiego. Ravindra Gujar, Senior Scientist at Onchilles, gave a talk titled, “N17350 - A Novel Therapeutic Modality That Selectively Kills Cancer Cells and Induces Potent Anti-Tumor Immunity to Eradicate Tumors” If you missed it, read our recent data release: https://lnkd.in/gDzd42Fk #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

Our cofounders chatted with San Diego Business Journal about our recent #AACR24 data showing our lead drug candidate works across many cancer types to kill tumor cells but leave healthy cells alone – as well as how our upcoming clinical trial could quickly yield proof-of-concept data. Read the article here (subscription may be required): https://lnkd.in/gR-rCQzE #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

We presented at #AACR24 new preclinical data for tumor-directed N17350 and systemically delivered N17465 demonstrating the potential for potent and tumor-selective treatment for a wide range of cancers. Key points: ?? Tumor-directed N17350 and systemically delivered N17465 are based on the breakthrough discovery of a novel innate immune mechanism of action, which activates cell death pathways specific to cancer cells ?? New preclinical data demonstrate direct and tumor-selective efficacy of N17350 in both chemotherapy-na?ve and -experienced ovarian cancer patient cells and cell-derived xenograft (CDX) models? ?? First data from the N17465 program demonstrate that the advanced drug lead can be delivered intravenously (IV) to induce potent single agent efficacy resulting from direct cancer cell killing and induction of anti-tumor immunity across a range of solid tumor models ?? Onchilles is on-track to initiate first-in-human clinical trials this year to evaluate N17350 in skin cancers, head and neck cancer, and triple-negative breast cancer Read the release here: https://lnkd.in/gDzd42Fk #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer